In addition to ibrutinib, people with M-CLL, devoid of TP53 aberrations and fit adequate to tolerate FCR therapy, should still be excellent candidates with the latter, Together with the gain remaining this procedure may be done in 6 months although ibrutinib needs to be taken indefinitely. This feature can be especially beneficial for non-compliant